How do Abl family kinases regulate cell shape and movement?

Trends in Cell Biology

Volumn 14, Issue 1, 2004, Pages 36-44

  Hernández, Samuel E ^a   Krishnaswami, Maithreyi ^a   Miller, Ann L ^a   Koleske, Anthony J ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ADAPTOR PROTEIN; BCR ABL PROTEIN; CELL ADHESION MOLECULE; CELL RECEPTOR; DROSOPHILA PROTEIN; GROWTH FACTOR; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; IMATINIB; PROTEIN ARG; PROTEIN CRK; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; REGULATOR PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

AUTOPHOSPHORYLATION; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL CULTURE; CELL MATURATION; CELL MOTILITY; CELL SHAPE; CELL SURFACE; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; CRYSTALLOGRAPHY; CYTOSKELETON; DROSOPHILA; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; GENETIC CONSERVATION; HUMAN; LEUKEMIA CELL; MORPHOGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SRC HOMOLOGY DOMAIN; VERTEBRATE;

VERTEBRATA;

EID: 0346496472     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcb.2003.11.003     Document Type: Review

References (71)

1. Hantschel O., et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell. 112:2003;845-857.
2. Nagar B., et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 112:2003;859-871.
3. Pendergast A.M. The Abl family kinases: mechanisms of regulation and signaling. Adv. Cancer Res. 85:2002;51-100.
4. Van Etten R.A., et al. The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. J. Cell Biol. 124:1994;325-340.
5. Wang Y., et al. The Abl-related gene (Arg) nonreceptor tyrosine kinase uses two F-actin-binding domains to bundle F-actin. Proc. Natl. Acad. Sci. U. S. A. 98:2001;14865-14870.
6. Gertler F.B., et al. Drosophila abl tyrosine kinase in embryonic CNS axons: a role in axonogenesis is revealed through dosage-sensitive interactions with disabled. Cell. 58:1989;103-113.
7. Wen S.T., et al. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J. 15:1996;1583-1595.
8. Taagepera S., et al. Nuclear-cytoplasmic shuttling of c-Abl tyrosine kinase. Proc. Natl. Acad. Sci. U. S. A. 95:1998;7457-7462.
9. Van Etten R.A., et al. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell. 58:1989;669-678.
10. Lewis J.M., et al. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc. Natl. Acad. Sci. U. S. A. 93:1996;15174-15179.
11. Koleske A.J., et al. Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron. 21:1998;1259-1272.
12. Van Etten R.A. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol. 9:1999;179-186.
13. Advani A.S., Pendergast A.M. Bcr-Abl variants: biological and clinical aspects. Leuk. Res. 26:2002;713-720.
14. Cazzaniga G., et al. The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood. 94:1999;4370-4373.
15. Iijima Y., et al. A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation. Blood. 95:2000;2126-2131.
16. McWhirter J.R., Wang J.Y. Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol. Cell. Biol. 11:1991;1553-1565.
17. Jousset C., et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J. 16:1997;69-82.
18. Chopra R., et al. Biology of BCR-ABL. Blood Rev. 13:1999;211-229.
19. Salgia R., et al. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene. 11:1995;1149-1155.
20. Salgia R., et al. BCR/ABL induces multiple abnormalities of cytoskeletal function. J. Clin. Invest. 100:1997;46-57.
21. Salesse S., Verfaillie C.M. Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CML. Oncogene. 21:2002;8605-8611.
22. Lanier L.M., Gertler F.B. From Abl to actin: Abl tyrosine kinase and associate proteins in growth cone motility. Curr. Opin. Neurobiol. 10:2000;80-87.
23. Grevengoed E.E., et al. Abelson kinase regulates epithelial morphogenesis in Drosophila. J. Cell Biol. 155:2001;1185-1198.
24. Liebl E.C., et al. Dosage-sensitive, reciprocal genetic interactions between the Abl tyrosine kinase and the putative GEF trio reveal trio's role in axon pathfinding. Neuron. 26:2000;107-118.
25. Plattner R., et al. A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1. Nat. Cell Biol. 5:2003;309-319.
26. Tybulewicz V.L., et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 65:1991;1153-1163.
27. Li B., et al. Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat. Genet. 24:2000;304-308.
28. Schwartzberg P.L., et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell. 65:1991;1165-1175.
29. Hardin J.D., et al. Abnormal peripheral lymphocyte function in c-abl mutant mice. Cell. Immunol. 172:1996;100-107.
30. Moresco E.M., et al. Abl family nonreceptor tyrosine kinases modulate short-term synaptic plasticity. J. Neurophysiol. 89:2003;1678-1687.
31. Plattner R., et al. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 13:1999;2400-2411.
32. Woodring P.J., et al. Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J. Cell Biol. 156:2002;879-892.
33. Kain K.H., Klemke R.L. Inhibition of cell migration by Abl family tyrosine kinases through uncoupling of Crk-CAS complexes. J. Biol. Chem. 276:2001;16185-16192.
34. Frasca F., et al. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor. Oncogene. 20:2001;3845-3856.
35. Moresco, E.M. and Koleske, A.J. Regulation of neuronal morphogenesis and synaptic function by Abl family kinases. Curr. Opin. Neurobiol. (in press).
36. Alexandropoulos K., Baltimore D. Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related protein. Sin. Genes Dev. 10:1996;1341-1355.
37. Moarefi I., et al. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature. 385:1997;650-653.
38. Dorey K., et al. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene. 20:2001;8075-8084.
39. Tanis K.Q., et al. Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol. Cell. Biol. 23:2003;3884-3896.
40. Brasher B.B., Van Etten R.A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 275:2000;35631-35637.
41. Furstoss O., et al. c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J. 21:2002;514-524.
42. Kaibuchi K., et al. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu. Rev. Biochem. 68:1999;459-486.
43. Etienne-Manneville S., Hall A. Rho GTPases in cell biology. Nature. 420:2002;629-635.
44. Chang J.H., et al. c-Src regulates the simultaneous rearrangement of actin cytoskeleton, p190RhoGAP, and p120RasGAP following epidermal growth factor stimulation. J. Cell Biol. 130:1995;355-368.
45. Harnois T., et al. Differential interaction and activation of Rho family GTPases by p210Bcr-Abl and p190Bcr-Abl. Oncogene. 22:2003;6445-6454.
46. Bassermann F., et al. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway. J. Biol. Chem. 277:2002;12437-12445.
47. Skorski T., et al. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc. Natl. Acad. Sci. U. S. A. 95:1998;11858-11862.
48. Renshaw M.W., et al. Rac is required for v-Abl tyrosine kinase to activate mitogenesis. Curr. Biol. 6:1996;76-83.
49. Ridley A.J., et al. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 70:1992;401-410.
50. Burton E.A., et al. Abl tyrosine kinases are required for infection by Shigella flexneri. EMBO J. 22:2003;5471-5479.
51. Matsuda M., et al. Two species of human CRK cDNA encode proteins with distinct biological activities. Mol. Cell. Biol. 12:1992;3482-3489.
52. Sakai R., et al. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J. 13:1994;3748-3756.
53. Feller S.M., et al. c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J. 13:1994;2341-2351.
54. Kiyokawa E., et al. Activation of Rac by a Crk SH3-binding protein, DOCK180. Genes Dev. 12:1998;3331-3336.
55. Shi Y., et al. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev. 9:1995;2583-2597.
56. Dai Z., Pendergast A.M. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev. 9:1995;2569-2582.
57. Stradal T., et al. The Abl interactor proteins localize to sites of actin polymerization at the tips of lamellipodia and filopodia. Curr. Biol. 11:2001;891-895.
58. Kwiatkowski A.V., et al. Function and regulation of Ena/VASP family proteins. Trends Cell Biol. 13:2003;386-392.
59. Tani K., et al. Abl interactor 1 promotes tyrosine 296 phosphorylation of mammalian Enabled (Mena) by c-Abl kinase. J. Biol. Chem. 278:2003;21685- 21692.
60. Juang J.L., Hoffmann F.M. Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity. Oncogene. 18:1999;5138-5147.
61. Gertler F.B., et al. Genetic suppression of mutations in the Drosophila abl proto-oncogene homolog. Science. 248:1990;857-860.
62. Comer A.R., et al. Phosphorylation of Enabled by the Drosophila Abelson tyrosine kinase regulates the in vivo function and protein-protein interactions of Enabled. Mol. Cell. Biol. 18:1998;152-160.
63. Scita G., et al. EPS8 and E3B1 transduce signals from Ras to Rac. Nature. 401:1999;290-293.
64. Kunda P., et al. Abi, Sra1, and Kette control the stability and localization of SCAR/WAVE to regulate the formation of actin-based protrusions. Curr Biol. 13:2003;. Published online October 13, 2003.
65. Rogers S.L., et al. Molecular requirements for actin-based lamella form in Drosophila S2 cells. J. Cell Biol. 162:2003;1079-1088.
66. Westphal R.S., et al. Scar/Wave-1 a Wiskott-Aldrich syndrome protein, assembles an actin-associated multi-kinase scaffold. EMBO J. 19:2000;4589-4600.
67. Rodriguez O.C., et al. Conserved microtubule-actin interactions in cell movement and morphogenesis. Nat. Cell Biol. 5:2003;599-609.
68. Wills Z., et al. A Drosophila homolog of cyclase-associated proteins collaborates with the Abl tyrosine kinase to control midline axon pathfinding. Neuron. 36:2002;611-622.
69. Woodring P.J., et al. Inhibition of c-Abl tyrosine kinase activity by filamentous actin. J. Biol. Chem. 276:2001;27104-27110.
70. Ting A.Y., et al. Genetically encoded fluorescent reports of protein tyrosine kinase activities in living cells. Proc. Natl. Acad. Sci. U. S. A. 98:2001;15003-15008.
71. O'Dwyer M.E., et al. STI571 as a targeted therapy for CML. Cancer Invest. 21:2003;429-438.